Journal of Thoracic Oncology

Journal

Publication Venue For

  • Osimertinib for Leptomeningeal Disease in EGFR-Mutated NSCLC.  15:1705-1708. 2020
  • Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines.  15:1577-1598. 2020
  • Electromagnetic Navigation Bronchoscopy for Peripheral Pulmonary Lesions: One-Year Results of the Prospective, Multicenter NAVIGATE Study.  14:445-458. 2019
  • PD-L1 Expression Heterogeneity in Non–Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections.  13:1113-1120. 2018
  • Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer.  12:145-151. 2017
  • ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC: Topic: Medical Oncology..  11:S252-S253. 2016
  • Spontaneous pulmonary torsion secondary to left upper lobe malignancy.  10:1653-1654. 2015
  • Prognostic nomogram to predict survival after surgery for synchronous multiple lung cancers in multiple lobes.  10:338-345. 2015
  • Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer.  9:572-576. 2014
  • Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer..  9:572-576. 2014
  • Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patients.  8:1295-1307. 2013
  • Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: A lead-in study.  7:1406-1416. 2012
  • Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer.  5:1977-1985. 2010
  • Risk of recurrence of resected stage i non-small cell lung cancer in elderly patients as compared with younger patients.  4:1370-1374. 2009
  • Impact of race on outcomes of patients with non-small cell lung cancer.  3:711-715. 2008
  • A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer Scheduled to Receive First-Line Chemotherapy.  2:210-220. 2007
  • Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses.  1:701-711. 2006
  • International Standard Serial Number (issn)

  • 1556-0864
  • Electronic International Standard Serial Number (eissn)

  • 1556-1380